• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·KAEF.JK
Share

PT Kimia Farma Tbk Stocks

IDR 352Last Updated 09.11.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

IDR 116.90M

IDR 352
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Kimia Farma (Persero) Tbk, an Indonesian entity, is engaged in the manufacturing and sale of a diverse range of products, including pharmaceuticals, herbal remedies, iodine, salts, quinine and its derivatives, and vegetable oils. Its business operations are structured across several key divisions: Manufacturing, Distribution, Retail, and Other Services. Beyond these, the company's portfolio extends to the production and sale of generic, ethical, licensed, and narcotic pharmaceuticals, along with over-the-counter drugs, medical equipment, raw materials, and cosmetics. Its extensive distribution network ensures products reach various outlets, including pharmacies, hospital pharmacies, medical centers, and drugstores. Established in 1817, the company maintains its headquarters in Jakarta, Indonesia.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair va

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.11.2026 05:26

Nebius's Nvidia-backed competitor may postpone its IPO — The Telegraph

11.11.2026 02:45

CoreWeave exceeded Wall Street's expectations. Will this ease concerns about neo-clouds?

11.11.2026 02:17

Stocks fell, and bonds experienced one of their biggest sell-offs: the market is waiting for the Fed to act

11.11.2026 01:51

Money managers seek shelter from AI risks in emerging markets. What are they buying?

11.11.2026 00:09

Boeing books most October aircraft orders in almost three decades

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026